Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Core Insights - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [3][4]. Company Overview - Trevi Therapeutics is developing Haduvio™, which acts as a kappa agonist and mu antagonist (KAMA) targeting cough hypersensitivity through opioid receptors [3]. - The investigational therapy is not currently scheduled by the U.S. Drug Enforcement Agency [3][6]. Market Need - Chronic cough affects up to 85% of the 140,000 U.S. patients with IPF, leading to severe impacts on quality of life and potential disease progression [4]. - There are no approved therapies for chronic cough in IPF, and current off-label treatments offer minimal benefits [4]. - Refractory chronic cough impacts approximately 2-3 million adults in the U.S., causing significant social and economic burdens [5]. Upcoming Events - Trevi's senior management will attend several investor conferences in February 2025, including: - Piper Sandler Biopharma Mogul Summit (February 2-4, 2025) [2] - Oppenheimer Healthcare 2025 Winter CEO & Investor Summit (February 3-6, 2025) [2] - Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference (February 11-12, 2025) with a corporate presentation on February 11 [2].